Glenmark enters $19 million US drug segment with generic Methylene Blue Injection

Glenmark Pharmaceuticals, USA has launched a generic Methylene Blue Injection USP targeting a $19 million market in the US. The bioequivalent drug treats rare blood disorders and strengthens Glenmark's institutional portfolio.